- cafead   Nov 29, 2022 at 10:42: AM
via Envisagenics, an Artificial Intelligence ("AI")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Bristol-Myers Squibb (NYSE: BMY).
article source
article source